(R) -Efavirenz

(R) -Efavirenz ((R) -DMP 266) is a non-nucleoside reverse transcriptase inhibitor that acts by non-competitive inhibition of the viral enzyme. (R) -Efavirenz can be metabolized by CYP2B6 to 8-hydroxyefavirenz in a highly stereoselective manner. (R) -Efavirenz is promising to be a useful probe for the CYP2B6 active site and catalytic mechanisms[1][2].

Product Specifications

CAS Number

[154801-74-8]

Product Name Alternative

(R) -DMP 266; (R) -EFV; (R) -L-743726

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Reverse Transcriptase

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/r-efavirenz.html

Smiles

FC(F)(F)[C@]1(C2=CC(Cl)=CC=C2NC(O1)=O)C#CC3CC3

Molecular Formula

C14H9ClF3NO2

Molecular Weight

315.67

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Maggiolo F. Efavirenz. Expert Opin Pharmacother. 2007 Jun;8 (8) :1137-45.|[2]Wang PF, et al. Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry. Drug Metab Dispos. 2019 Oct;47 (10) :1195-1205. doi: 10.1124/dmd.119.086348. Epub 2019 Jul 19. Erratum in: Drug Metab Dispos. 2019 Oct;47 (10) :1231.